Cardiovascular Risks of Methylphenidate in Children with ADHD
DOI:
https://doi.org/10.12775/JEHS.2024.65.55139Keywords
ADHD, methylphenidate, cardiovascular risk, children, treatment, monitoringAbstract
Introduction: Attention Deficit Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental disorder affecting millions of children worldwide. Methylphenidate is one of the most prescribed medications for managing ADHD symptoms due to its proven efficacy. However, despite its widespread use and effectiveness, there are ongoing concerns about the cardiovascular safety of methylphenidate, particularly in pediatric populations. These concerns stem from reports of increased heart rate, elevated blood pressure, and, in rare cases, more severe cardiovascular events.
Aim of the Study: To review recent studies on the cardiovascular safety of methylphenidate in children with ADHD, synthesizing findings to inform clinical practice.
Materials and Methods: A comprehensive literature review was conducted, focusing on studies published in the last decade that investigated the cardiovascular effects of methylphenidate in children with ADHD.
Conclusion: The review highlights that while methylphenidate is generally well-tolerated, there are notable cardiovascular risks, particularly in susceptible children. These risks underscore the importance of thorough cardiovascular assessment and monitoring in children undergoing treatment with methylphenidate. The findings advocate for a balanced approach where the benefits of symptom management are weighed against potential cardiovascular risks. Clinicians are advised to adopt comprehensive monitoring strategies and consider individual risk factors when prescribing methylphenidate to children with ADHD.
References
Pereira Ribeiro, J., Arthur, E. J., Gluud, C., Simonsen, E., & Storebø, O. J. (2021). Does Methylphenidate Work in Children and Adolescents with Attention Deficit Hyperactivity Disorder?. Pediatric reports, 13(3), 434–443. https://doi.org/10.3390/pediatric13030050
Shin, J. Y., Roughead, E. E., Park, B. J., & Pratt, N. L. (2016). Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ (Clinical research ed.), 353, i2550. https://doi.org/10.1136/bmj.i2550
Türkmenoğlu, Y. E., Esedova, C., Akpinar, M., Uysal, T., & İrdem, A. (2020). Effects of medications on ventricular repolarization in children with attention deficit hyperactivity disorder. International clinical psychopharmacology, 35(2), 109–112. https://doi.org/10.1097/YIC.0000000000000288
Pierick, A. R., Lynn, M., McCracken, C. M., Oster, M. E., & Iannucci, G. J. (2021). Treatment of attention deficit/hyperactivity disorder in children with CHD. Cardiology in the young, 31(6), 969–972. https://doi.org/10.1017/S1047951120004965
Batra, A. S., Alexander, M. E., & Silka, M. J. (2012). Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason. Pediatric cardiology, 33(3), 394–401. https://doi.org/10.1007/s00246-012-0162-6
Graham, J., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Dittmann, R. W., Döpfner, M., Hamilton, R., Hollis, C., Holtmann, M., Hulpke-Wette, M., Lecendreux, M., Rosenthal, E., Rothenberger, A., Santosh, P., Sergeant, J., Simonoff, E., Sonuga-Barke, E., Wong, I. C., Zuddas, A., … European Guidelines Group (2011). European guidelines on managing adverse effects of medication for ADHD. European child & adolescent psychiatry, 20(1), 17–37. https://doi.org/10.1007/s00787-010-0140-6
Dalsgaard, S., Kvist, A. P., Leckman, J. F., Nielsen, H. S., & Simonsen, M. (2014). Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. Journal of child and adolescent psychopharmacology, 24(6), 302–310. https://doi.org/10.1089/cap.2014.0020
Winterstein, A. G., Gerhard, T., Kubilis, P., Saidi, A., Linden, S., Crystal, S., Zito, J., Shuster, J. J., & Olfson, M. (2012). Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ (Clinical research ed.), 345, e4627. https://doi.org/10.1136/bmj.e4627
Vitiello, B., Elliott, G. R., Swanson, J. M., Arnold, L. E., Hechtman, L., Abikoff, H., Molina, B. S., Wells, K., Wigal, T., Jensen, P. S., Greenhill, L. L., Kaltman, J. R., Severe, J. B., Odbert, C., Hur, K., & Gibbons, R. (2012). Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. The American journal of psychiatry, 169(2), 167–177. https://doi.org/10.1176/appi.ajp.2011.10111705
Omidi, N., Mojtaba Ghorashi, S., Zahedi Tajrishi, F., Effatpanah, M., Khatami, F., & Rafie Khorgami, M. (2021). Effects of methylphenidate on blood pressure, QT-interval, and cardiac output in ADHD diagnosed children: A three months' follow-up study. International journal of cardiology. Heart & vasculature, 34, 100805. https://doi.org/10.1016/j.ijcha.2021.100805
Cooper, W. O., Habel, L. A., Sox, C. M., Chan, K. A., Arbogast, P. G., Cheetham, T. C., Murray, K. T., Quinn, V. P., Stein, C. M., Callahan, S. T., Fireman, B. H., Fish, F. A., Kirshner, H. S., O'Duffy, A., Connell, F. A., & Ray, W. A. (2011). ADHD drugs and serious cardiovascular events in children and young adults. The New England journal of medicine, 365(20), 1896–1904. https://doi.org/10.1056/NEJMoa1110212
Habel, L. A., Cooper, W. O., Sox, C. M., Chan, K. A., Fireman, B. H., Arbogast, P. G., Cheetham, T. C., Quinn, V. P., Dublin, S., Boudreau, D. M., Andrade, S. E., Pawloski, P. A., Raebel, M. A., Smith, D. H., Achacoso, N., Uratsu, C., Go, A. S., Sidney, S., Nguyen-Huynh, M. N., Ray, W. A., … Selby, J. V. (2011). ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA, 306(24), 2673–2683. https://doi.org/10.1001/jama.2011.1830
Hennissen, L., Bakker, M. J., Banaschewski, T., Carucci, S., Coghill, D., Danckaerts, M., Dittmann, R. W., Hollis, C., Kovshoff, H., McCarthy, S., Nagy, P., Sonuga-Barke, E., Wong, I. C., Zuddas, A., Rosenthal, E., Buitelaar, J. K., & ADDUCE consortium (2017). Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. CNS drugs, 31(3), 199–215. https://doi.org/10.1007/s40263-017-0410-7
Vetter, V. L., Elia, J., Erickson, C., Berger, S., Blum, N., Uzark, K., Webb, C. L., American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee, & American Heart Association Council on Cardiovascular Nursing (2008). Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation, 117(18), 2407–2423. https://doi.org/10.1161/CIRCULATIONAHA.107.189473
Gibbons, R. D., Amatya, A. K., Brown, C. H., Hur, K., Marcus, S. M., Bhaumik, D. K., & Mann, J. J. (2010). Post-approval drug safety surveillance. Annual review of public health, 31, 419–437. https://doi.org/10.1146/annurev.publhealth.012809.103649
Schachter, H. M., Pham, B., King, J., Langford, S., & Moher, D. (2001). How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 165(11), 1475–1488.
Bourgeois, F. T., Kim, J. M., & Mandl, K. D. (2014). Premarket safety and efficacy studies for ADHD medications in children. PloS one, 9(7), e102249. https://doi.org/10.1371/journal.pone.0102249
Gray, M. A., & Critchley, H. D. (2007). Interoceptive basis to craving. Neuron, 54(2), 183–186. https://doi.org/10.1016/j.neuron.2007.03.024
Schelleman, H., Bilker, W. B., Kimmel, S. E., Daniel, G. W., Newcomb, C., Guevara, J. P., Cziraky, M. J., Strom, B. L., & Hennessy, S. (2012). Methylphenidate and risk of serious cardiovascular events in adults. The American journal of psychiatry, 169(2), 178–185. https://doi.org/10.1176/appi.ajp.2011.11010125
Hennissen, L., Bakker, M. J., Banaschewski, T., Carucci, S., Coghill, D., Danckaerts, M., Dittmann, R. W., Hollis, C., Kovshoff, H., McCarthy, S., Nagy, P., Sonuga-Barke, E., Wong, I. C., Zuddas, A., Rosenthal, E., Buitelaar, J. K., & ADDUCE consortium (2017). Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. CNS drugs, 31(3), 199–215. https://doi.org/10.1007/s40263-017-0410-7
McCarthy, S., Cranswick, N., Potts, L., Taylor, E., & Wong, I. C. (2009). Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug safety, 32(11), 1089–1096. https://doi.org/10.2165/11317630-000000000-00000
Habel, L. A., Cooper, W. O., Sox, C. M., Chan, K. A., Fireman, B. H., Arbogast, P. G., Cheetham, T. C., Quinn, V. P., Dublin, S., Boudreau, D. M., Andrade, S. E., Pawloski, P. A., Raebel, M. A., Smith, D. H., Achacoso, N., Uratsu, C., Go, A. S., Sidney, S., Nguyen-Huynh, M. N., Ray, W. A., … Selby, J. V. (2011). ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA, 306(24), 2673–2683. https://doi.org/10.1001/jama.2011.1830
Sayer, G. R., McGough, J. J., Levitt, J., Cowen, J., Sturm, A., Castelo, E., & McCracken, J. T. (2016). Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder. Journal of child and adolescent psychopharmacology, 26(10), 882–888. https://doi.org/10.1089/cap.2015.0264
Graham, J., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Dittmann, R. W., Döpfner, M., Hamilton, R., Hollis, C., Holtmann, M., Hulpke-Wette, M., Lecendreux, M., Rosenthal, E., Rothenberger, A., Santosh, P., Sergeant, J., Simonoff, E., Sonuga-Barke, E., Wong, I. C., Zuddas, A., … European Guidelines Group (2011). European guidelines on managing adverse effects of medication for ADHD. European child & adolescent psychiatry, 20(1), 17–37. https://doi.org/10.1007/s00787-010-0140-6
Hennissen, L., Bakker, M. J., Banaschewski, T., Carucci, S., Coghill, D., Danckaerts, M., Dittmann, R. W., Hollis, C., Kovshoff, H., McCarthy, S., Nagy, P., Sonuga-Barke, E., Wong, I. C., Zuddas, A., Rosenthal, E., Buitelaar, J. K., & ADDUCE consortium (2017). Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. CNS drugs, 31(3), 199–215. https://doi.org/10.1007/s40263-017-0410-7
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Adrianna Czachor, Elwira Servaas, Alicja Kotula, Mateusz Haber, Olga Grelewicz, Natalia Kucy, Adam Juśkiewicz, Paula Kula
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 205
Number of citations: 0
